This article was written by Dr. Jenya Antonova, head of Compass Strategy and Research Inc., as part of Psychedelic Health’s op-ed program. To submit article ideas, please email news@psychedelichealth.co.uk

The psychedelic sector stands at a critical point. Clinical trials suggest meaningful benefits in depressive, anxiety-, trauma-related, and substance use disorders—conditions marked by substantial morbidity, diminished quality of life, and impaired social and occupational functioning.

Psychedelic treatments aim to improve not only symptoms, but how people think, feel, relate, and function in the world. In other words, they aim to improve health in its fullest sense. Public narratives speak of great potential. Investors anticipate scale.

Yet effective long-term integration into healthcare systems will be driven not by enthusiasm or early efficacy signals alone. For that, psychedelic therapies must demonstrate measurable safety and improvements in health in a way that satisfies regulators, health technology assessment bodies, policymakers, clinicians, and patients.

Health is a very complex construct. It is lived and experienced by each of us uniquely. And that lived experience must be measured. This is not merely a philosophical argument—it encapsulates the methodological and practical aspects of how lived experiences are measured in clinical trials.

In some therapeutic areas, like oncology, infectious diseases, diabetes, and endocrine autoimmune conditions, objective laboratory values, imaging, or physiological assessments can assess treatment response. In contrast, depressive, anxiety-, trauma-related, and substance-use disorders lack validated objective endpoints that confirm recovery.

Therefore, the assessment of risks and benefits of psychedelic medicine will ultimately rest on how convincingly it translates subjective assessment of well-being into rigorous patient experience data that matter to all stakeholders. 

However, different stakeholders interpret patient experience data through different lenses.

Assessing Effects: Clinically Meaningful vs. Statistically Significant 

Regulators determine whether substantial evidence of effectiveness and acceptable safety warrant authorization for use in humans. In the United States, the FDA’s Patient-Focused Drug Development framework makes clear that clinical outcome assessments used to support labeling claims must capture outcomes that are meaningful to patients—specifically how patients feel and function.

The instrument for clinical outcome assessment must be fit for purpose, with demonstrated validity, reliability, and responsiveness in the target population. In Europe, the EMA reflection paper on the use of health-related quality-of-life measures in the evaluation of medicinal products underscores that patient-reported outcomes must be methodologically sound and clinically interpretable to inform regulatory decision-making. Beyond reliability and validity, scoring must be clearly interpretable to ensure that demonstrated effects are clinically meaningful, not merely statistically significant.

Historically, regulatory objectives around patient experience data have centered on labeling. Yet comprehensive patient experience data can also enhance the evidentiary robustness of the entire submission. It includes evidence of holistic treatment effects, psychiatric safety, durability of benefit, the potential influence of functional unblinding and expectation bias—considerations that featured prominently in the FDA’s 2024 review of MDMA-assisted therapy for PTSD.

From Approval to Rollout and Patient Uptake

Once regulatory approval is granted, the next critical milestone is reimbursement. The health technology assessment (HTA) agencies worldwide place significant weight on patient experience data, though their approaches vary.

The German AMNOG legislation and the EU Joint Clinical Assessment framework require patient-relevant outcomes, including morbidity and health-related quality of life. Other agencies such as TLV (Sweden), ZIN (the Netherlands), NoMA (Norway), SMC (Scotland), NCPE (Ireland), HAS (France), and NICE (the UK) evaluate patient experience data within their clinical or economic appraisals.

Health-utility estimates used in cost-utility analyses are typically derived from patient experience data. All HTA bodies demand that patient experience data be of high methodological rigor, consistent with standards established by regulatory agencies. 

Along with the HTA agencies, policy makers will decide whether psychedelic medicine remains niche and tightly constrained, or becomes responsibly integrated into mainstream care. Their decisions will hinge on whether the field can provide rigorous evidence of long-term safety, durability of effect, real-world functional recovery, and abuse potential—areas for which long-term patient experience data will be critical.

Approval, however, does not guarantee wide uptake. Ultimately, patients decide whether to pursue a therapy. Patients want to understand not only “Does it work?” but also “What will it feel like? How will it change my daily life? What challenges might I face?” 

Here, credible data on direct lived experiences can replace anecdote and media narratives, enabling patients to make well-informed decisions grounded in what matters to them most.

Clinicians bridge the gap between clinical trial data and the patient taking the treatment. In psychedelic medicine, they not only prescribe treatments, determine dosing, but also facilitate and monitor sessions, advise patients, and monitor the effect of treatment. Rigorous patient experience data enables clinicians to merge evidence-based decision-making with a patient-centered approach.

Understanding Patient Experience Data

How, then, can patient experience data be demonstrated in practice?

The most common and most influential approach is for Phase 3 to generate evidence-based instruments for clinical outcome assessment, which include clinician-reported outcomes, and patient-reported outcomes. These instruments can—and often do—support primary, secondary, or exploratory endpoints rendering completeness to the risk-benefit assessment. 

Qualitative research offers a scientific framework for systematically capturing patients’ lived experiences. Qualitative evidence is a must for establishing content validity of instruments for patient-reported outcomes and clinician-reported outcomes that support clinical trial endpoints. 

In-trial interviews can take clinical trial data to the next level: contextualize quantitative findings, deepen understanding of patient experience with the treatment, and generate critical evidence for the interpretation of treatment effect. In psychedelic medicine, qualitative insights can be particularly powerful when systematically collected and analyzed.

Patient preference research represents another powerful tool. Preference studies can quantify how patients weigh different treatment attributes—safety, efficacy, overall treatment experience, and long-term outcomes. Understanding of patient trade-offs can inform regulatory, reimbursement, policy decision-making and clinical counseling.

What does it all mean for the strategy?

The central lesson we have learned from other therapeutic areas, which applies acutely to psychedelics, is that patient experience data must be intentional. It requires early planning, validated instruments, clear endpoint hierarchies, and alignment with regulatory and HTA expectations.

The lack of comprehensive patient experience data can inhibit regulatory and HTA reviews and result in suboptimal access outcomes. Yet launching patient experience data strategy at Phase 3 is likely too late.

Phase 3 are confirmatory trials. By then, the instruments must be validated, endpoints pre-specified, statistical power estimated, and clinically meaningful change established. If these decisions are not pre-determined, Phase 3 carries avoidable risks that are costly and highly visible.

Phase 2 should therefore serve a dual purpose: to explore efficacy and to establish the patient experience data framework. This includes validating clinical outcome assessments, testing their performance in the target population, and defining thresholds for meaningful change that can be carried forward into confirmatory trials. Therefore, sponsors should start planning patient experience data strategy very early. 

For investors, an early patient experience data strategy can signal strategic maturity, foresight into the future regulatory and HTA requirements, and understanding of what will drive the value in a field subjected to intense public scrutiny and regulatory attention. 

As psychedelic therapies confront heightened scrutiny, they must show their ability to transform patient lives and improve their functioning in society. For that, rigorous patient experience data is not optional. It is a winning card.

Illustration made using generative AI tools.

This article was submitted by by Dr Shoona Vincent, Vice President of Clinical Science at MAC Clinical Research, as part of Psychedelic Health’s op-ed program. To submit article ideas, please send us an email to news@psychedelichealth.co.uk

The psychedelic research renaissance is well underway, with clinical trials investigating psilocybin, MDMA and other compounds yielding promising results for conditions such as treatment-resistant depression, PTSD and anxiety. Yet as a clinical scientist working at the intersection of research and care, I’m increasingly aware that the biggest challenge may lie not in the trials themselves, but in what happens next.

How do we responsibly, ethically and effectively translate psychedelic research into real-world healthcare settings?

While data from early-phase trials has sparked optimism, moving from controlled environments into the complexity of public health systems like the NHS is far from straightforward. Without careful attention to this translational gap, we risk undermining both patient safety and scientific credibility.

The Unique Challenges of Psychedelic Treatments

Clinical trials, by design, operate under highly controlled conditions. Participant selection is highly controlled and carefully managed. Interventions are delivered according to strict protocols. Staff are extensively trained, and safety oversight is constant. These are necessary conditions for generating reliable data, particularly when dealing with powerful psychoactive compounds.

But real-world clinical care is not a controlled environment. In the UK, for example, the NHS is already stretched for resources, and psychedelic therapies, which often require extended therapeutic sessions, careful preparation and post-treatment integration, are resource intensive. Even in private healthcare, logistical and legal barriers persist. Scaling psychedelic therapy demands a reimagining of how such care could be delivered.

The patient population in clinical trials is also often narrow by necessity. In practice, individuals seeking psychedelic treatment may present with comorbidities, complex trauma histories, or physical health conditions that were excluded from trials. These variables challenge both safety assumptions and efficacy predictions.

Psychedelic compounds are not like conventional medicines; their effects are profoundly shaped by context: the “set and setting” often referenced in psychedelic literature. Ensuring appropriate therapeutic environments, including trained facilitators and immediate access to psychiatric or medical support, is essential to minimising risk.

From my experience in psychedelic clinical research, one of the most underestimated logistical challenges is staffing. Delivering psychedelic therapy safely requires coordination between facilitators, psychiatrists, raters, medics and support staff, often outside standard working hours. Screening processes are necessarily selective to manage this risk and ensure participants have the appropriate support systems in place during and after dosing.

In trials we also confront the issue of functional unblinding, a challenge unique to psychedelics due to their unmistakable psychoactive effects. This complicates assessments of treatment efficacy and placebo effects. To counter this, we’ve found it crucial to use blinded outcome raters and maintain strict controls around data collection.

Translating all of this into a typical mental health care setting will be no easy task.

Another challenge lies between the standardisation required in research and the personalisation needed in practice. Psychedelic therapies elicit deeply individual experiences, influenced by a person’s psychological background, life history, cultural identity and expectations. Unlike pharmacotherapies with more predictable dose-response curves, psychedelics can vary dramatically in effect, even with identical doses.

This makes it difficult to produce a “one-size-fits-all” treatment model. We must acknowledge that understanding efficacy means going beyond statistical outcomes and engaging with the lived experience of participants. Some may benefit from one or two sessions; others may require longer integration support. For some, these therapies may not be appropriate at all.

This has long been a challenge in mental health care, but psychedelics magnify it. We need to find ways to balance generalisable findings from randomised controlled trials with flexible, context-sensitive approaches in practice. The aim is not to compromise on scientific quality, but to build on it by acknowledging that complexity and subjectivity are part of the therapeutic process.

To bridge the gap between clinical trials and real-world application, we need to diversify our approach to evidence generation. In my opinion traditional outcome measures, while valuable, are not enough.

We need to understand the phenomenology of psychedelic experiences, how people interpret and integrate these sessions into their lives, how meaning is constructed and how this affects therapeutic outcomes. Qualitative methods can surface insights that quantitative data often misses: fears, breakthroughs, cultural dimensions and personal transformations that shape the healing process.

Only by incorporating these insights can we develop more nuanced clinical guidance, train facilitators appropriately, and create ethical frameworks for expanded access.

What Comes Next?

We are at a pivotal moment. The enthusiasm surrounding psychedelic therapies is justified but must be tempered by realism and responsibility. Moving from trial to treatment will require more than good data; it demands thoughtful implementation, strict safety protocols, flexible care models and a willingness to embrace complexity.

At a recent CNS Summit, there was consensus among attendees that while psychedelic-assisted therapies hold great promise, psychotherapy may not be required in all general practice contexts. This reinforces the need to avoid rigid, one-size-fits-all models and instead prioritise flexible, patient-centred approaches grounded in both evidence and clinical judgement.

As researchers, clinicians, and policymakers, we must collaborate across disciplines to ensure that psychedelic care is not only effective, but also equitable, ethical, and evidence informed. The success of this field will depend not just on what we discover in the lab but on how we adapt it to meet the needs of real people, in real clinical settings.

Dr Shoona Vincent has over 35 years of experience in the pharmaceutical and CRO industry, leading global clinical research programmes across multiple therapeutic areas. Since joining MAC Clinical Research in 2014, Dr Vincent has overseen several psychedelic studies and continues to advise sponsors as a Therapeutic and Scientific Advisor.

Image from Pexels.

This article was submitted by Lucy da Silva, Psychedelic Support Therapist and CEO Silva Wellness, as part of Psychedelic Health’s op-ed program. To submit article ideas, please email news@psychedelichealth.co.uk

I once was addicted to alcohol and drugs, which I was lucky enough to overcome through the 12-step programme. This journey was steeped in peer support and a real sense of community. Over the past five or so years, I have also had my fair share of psychedelic healing experiences, most of them in group settings.

Entering this sphere, I was fortunate to come from a place of internal containment and grounding, since my healing journey had begun long before my first psychedelic experience in a ceremonial setting. As a qualified and experienced psychotherapist, I was well versed in self-care, the analytical lens of Jungian interpretation and, most importantly, trauma knowledge and containment.

What these seeds of experience began to sow for me was an awareness of how clinical excitement can sometimes overshadow the slower work of building adequate systems that protect, hold and integrate – striking the delicate balance between respect for indigenous traditions and the demands of medicine-inspired healing. As a therapist, my work often focuses on the healing that takes place after harm has occurred. But my own experiences in medicine ceremonies (some profound and safe, others not so much) led me to wonder: what would it mean to design safety from the ground up?

The psychedelic field has made extraordinary progress in just a few years. Regulatory frameworks are evolving, clinical trials are expanding, and public interest is growing faster than any of us could have predicted. There’s a palpable sense of momentum—of medicine, culture and consciousness beginning to reconnect. The renaissance is not on its way—it is here! 

Come meet the leaders shaping the future of psychedelic medicine. Join PSYCH Symposium: London 2025, December 4 at Conway Hall.

Yet much of this progress still takes place within the same paradigms that shaped twentieth-century psychiatry: models focused on efficacy and access, rather than on the deeper architecture of care. We talk about scaling treatments, but rarely about scaling safety—about designing systems that protect psychological integrity as much as they deliver clinical outcomes.

The conversation about psychedelic medicine often stops at the clinic door. But the next frontier of innovation isn’t pharmacological; it’s relational, community-driven and systemic. It’s about how we build environments that recognise trauma not as an exception, but as the context from which most people seek healing. This is especially relevant when utilising psychedelics for the treatment of substance use disorders.

Co-Design Workshops: Trauma-Informed Care and Community Integration in Psychedelic Therapy

When we had the opportunity to apply for a government-backed R&D grant, it offered the chance to formalise what I had personally seen and encountered in group settings—as well as what I had heard through anecdotal conversations with individuals I met along the way, including clients who needed help processing uncontained trauma after group experiences.

With the grant focusing on individuals suffering from substance use disorders, I was motivated to propose a trauma-informed model in a group setting supported by community integration initiatives. I also wanted to address the elephant in the room: expanding access. With ketamine treatment via IV costing around £10,000 in the UK, affordability remains a serious issue. My goal was to explore how we can scale treatment options safely. We need to ensure that the very systems we design to help people heal do not inadvertently replicate harm.

Rather than studying participants, we’ll be studying systems, and asking what those systems need to look like to prevent harm before it happens.

Our study (scheduled to kick off in November 2025), Co-Design Workshops: Trauma-Informed Care and Community Integration in Psychedelic Therapy, aims to explore how safety can be intentionally designed into emerging psychedelic care models before they become mainstream. It will run as follows:

1. Three stakeholder groups (clinicians, peer facilitators and mental health service designers) will participate in a series of co-design workshops.
2. Using journey mapping and system mapping, the sessions will explore how trauma-informed principles can guide safe, accessible models for group-based ketamine lozenge therapy (KLT).
3. The aim is to co-create conceptual frameworks that integrate ethical design, accessibility and community wisdom from the outset.

What we hope to learn is that safety is relational, shaped by culture and trust just as much as by clinical control. Trauma-informed practice, emotional readiness, education, and attention to set and setting before any medicine is ingested should form vital components of integration.

Promoting integration as preparation—as the precursor to treatment, as a modality in itself—mirrors what the 12-step programme does so well. Peer-led community, robust support and follow-up systems could become the scaffolding that extends care beyond the session, supporting longevity in healing.

This also ties into the concept of reducing hierarchy by amplifying lived expertise and modelling the inclusivity that psychedelic care must embody. It can help individuals lean towards treatment rather than resist it—a common challenge in both community-led and private addiction treatment programmes.

As the long-term aim of this project is to align proposed frameworks with voluntary sector and NHS infrastructure, we envisage that it could inform future service delivery and policy development. Most importantly, we hope to begin a wider discussion about how future frameworks can be wrapped in nurturing ethics and, above all, safety.

If we can integrate trauma-informed principles from the outset, the future of psychedelic therapy could look very different. We might see small, community-based groups supported by skilled facilitators who understand containment as much as chemistry. Integration models could become embedded within peer networks, where shared experience is part of the medicine itself.

Services could evolve through co-design rather than correction, shaped by lived wisdom as much as professional expertise. In this vision, innovation means not just expanding access, but building safety, inclusion and care by design.

Because the psychedelic renaissance will only ever be as safe as the systems that hold it and designing those systems is the real frontier.

As this project begins, we have a rare opportunity to slow down—to listen, collaborate and build the ethical foundations before psychedelic care becomes fully mainstream. Trauma-informed design reminds us that safety is not simply the absence of harm, but the presence of trust, transparency and relationship.

If we can weave those qualities into the structures that support psychedelic work, from the clinic to the community, we stand a chance of creating a field that heals without replicating old wounds.

This study is just the first step, but it marks an invitation to the wider field: to design consciously, collectively and with care at the centre.

Because the question is no longer whether psychedelics can heal, it’s whether we can design the systems that allow that healing to endure.

Image by andreas160578 from Pixabay